Clinical Trials
47 trialsBASECAMP-1
A2 Biotherapeutics Inc.
DESCENT-1
A2 Biotherapeutics Inc.
A Study of DEG6498 in Participants With Solid Tumors
Degron Therapeutics Co.
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
ModeX Therapeutics, An OPKO Health Company
ELEPHAS-02
Elephas
TEJAS-2
Aurigene Discovery Technologies Limited
STEALTH-001
KaliVir Immunotherapeutics
Psilocybin-Assisted Psychotherapy in Cancer Patients With Adjustment Disorder
Psyence Australia Pty Ltd
A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.
Pfizer
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
Tizona Therapeutics, Inc
CAMPERR
Adela, Inc
SL-28 for Advanced Solid Tumours
Second Life Therapeutics
ELEPHAS-05
Elephas
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers
Novartis
Medtronic Hugoâ„¢ Robotic Assisted Surgery (RAS) System in Urologic Surgery (Expand URO)
Medtronic - MITG
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Massive Bio, Inc.
A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
Sensei Biotherapeutics, Inc.
Tempus Priority Study: A Pan-tumor Observational Study
Tempus AI
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
Elevation Oncology
A Post-marketing Surveillance to Assess the Safety and Effectiveness of Zirabev in Domestic Patients With Various Cancer
Pfizer
First-in-human Phase I Study to Evaluate Safety, Tolerability and Antineoplastic Activity of OATD-02 in Patients with Selected Advanced And/or Metastatic Solid Tumours
Molecure S.A.
ROOT
Taproot Health
Study of Continuous OSI-906 Dosing
Astellas Pharma Inc
Study of Intermittent OSI-906 Dosing
Astellas Pharma Inc
RADIANT
DxTerity Diagnostics
At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions
Sanguine Biosciences
A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors
Sumitomo Pharma America, Inc.
A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies
Celldex Therapeutics
CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers
Corvus Pharmaceuticals, Inc.
A Clinical Trial of KVA12123 Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)
Kineta Inc.
A Study of JNJ-78306358 in Participants With Advanced Stage Solid Tumors
Janssen Research & Development, LLC
Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S
Quadriga Biosciences, Inc.
Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors
Exact Sciences Corporation
Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566
Pfizer
PIONEER
SpeciCare
A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell Carcinoma and Ovarian Clear Cell Carcinoma
Celldex Therapeutics
Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies
Celgene
Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma
Amgen
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Amgen
Effects of STM 434 Alone or in Combination With Liposomal Doxorubicin in Patients With Ovarian Cancer or Other Advanced Solid Tumors
Santa Maria Biotherapeutics
Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma
Valerio Therapeutics
Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors
Valerio Therapeutics
Safety and Efficacy Study of ALT-801 to Treat Progressive Metastatic Malignancies
Altor BioScience
A Study of ZYC300 Administered With Cyclophosphamide Pre-Dosing
Eisai Inc.
Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2
Takeda
Phase 1 Study of OSI-930 in Cancer Patients
Astellas Pharma Inc
Study of Motexafin Gadolinium and Docetaxel for Advanced Cancer
Pharmacyclics LLC.